Alamar biosciences partners with abcam to drive understanding of the human proteome

Fremont, calif. and cambridge, england, jan. 4, 2022 /prnewswire/ -- alamar biosciences (alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and abcam (aim: abc) (nasdaq: abcm), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of the human proteome.
ABCM Ratings Summary
ABCM Quant Ranking